• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy".

作者信息

Yeong Joe, Teo Chong Boon, Tay Ryan Yong Kiat, Tan Benjamin Kye Jyn, Chan Yiong Huak, Smyth Elizabeth C, Sundar Raghav

机构信息

Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore.

Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore.

出版信息

Gastric Cancer. 2022 Nov;25(6):1133-1135. doi: 10.1007/s10120-022-01343-4. Epub 2022 Sep 24.

DOI:10.1007/s10120-022-01343-4
PMID:36152122
Abstract
摘要

相似文献

1
Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy".回复：致编辑的信，关于文章《PD-L1免疫组化检测方法的选择对胃癌免疫治疗临床适用性的影响》
Gastric Cancer. 2022 Nov;25(6):1133-1135. doi: 10.1007/s10120-022-01343-4. Epub 2022 Sep 24.
2
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.PD-L1 免疫组化检测方法的选择影响胃癌免疫治疗的临床适用性。
Gastric Cancer. 2022 Jul;25(4):741-750. doi: 10.1007/s10120-022-01301-0. Epub 2022 Jun 4.
3
Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.通过肿瘤免疫微环境的多维分析预测胃癌对免疫治疗的反应。
Nat Commun. 2022 Aug 18;13(1):4851. doi: 10.1038/s41467-022-32570-z.
4
Immunotherapy in advanced gastric cancer, is it the future?免疫治疗在晚期胃癌中的应用，是否代表未来？
Crit Rev Oncol Hematol. 2019 Jan;133:25-32. doi: 10.1016/j.critrevonc.2018.10.007. Epub 2018 Nov 2.
5
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer.基于生物标志物的胃癌化疗免疫治疗。
Int J Clin Oncol. 2024 Jul;29(7):865-872. doi: 10.1007/s10147-024-02525-z. Epub 2024 Apr 22.
6
Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.敲低人胃癌细胞中的程序性死亡配体1（PD-L1）可抑制肿瘤进展并提高对细胞因子诱导的杀伤（CIK）疗法的细胞毒性敏感性。
Cell Physiol Biochem. 2017;41(3):907-920. doi: 10.1159/000460504. Epub 2017 Feb 20.
7
Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.胃肠胰神经内分泌肿瘤中程序性细胞死亡配体-1的表达
J BUON. 2019 Mar-Apr;24(2):779-790.
8
Remnant gastric cancer: a neglected group with high potential for immunotherapy.残胃癌：一个被忽视但免疫治疗潜力巨大的群体。
J Cancer Res Clin Oncol. 2020 Dec;146(12):3373-3383. doi: 10.1007/s00432-020-03322-7. Epub 2020 Jul 15.
9
The rapidly evolving landscape of advanced gastric cancer therapy.晚期胃癌治疗领域迅速演变的格局。
Future Oncol. 2022 Apr;18(12):1413-1416. doi: 10.2217/fon-2021-1499. Epub 2022 Feb 7.
10
Biomarkers of immunotherapy response in breast cancer beyond PD-L1.乳腺癌免疫治疗反应的生物标志物：超越 PD-L1。
Breast Cancer Res Treat. 2022 Jan;191(1):39-49. doi: 10.1007/s10549-021-06421-2. Epub 2021 Oct 21.

引用本文的文献

1
[Sphingosine kinase-1 regulates migration and invasion of gastric cancer cells targeting the nuclear factor-κB signaling pathway].[鞘氨醇激酶-1通过靶向核因子-κB信号通路调控胃癌细胞的迁移和侵袭]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Nov 20;44(11):2163-2171. doi: 10.12122/j.issn.1673-4254.2024.11.13.
2
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.癌症免疫治疗学会（SITC）临床实践指南：免疫治疗治疗胃肠道癌。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006658.
3
Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?

本文引用的文献

1
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.PD-L1 免疫组化检测方法的选择影响胃癌免疫治疗的临床适用性。
Gastric Cancer. 2022 Jul;25(4):741-750. doi: 10.1007/s10120-022-01301-0. Epub 2022 Jun 4.
2
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer.胃癌中单细胞谱系状态、肿瘤微环境和亚型特异性表达程序图谱。
Cancer Discov. 2022 Mar 1;12(3):670-691. doi: 10.1158/2159-8290.CD-21-0683.
3
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
胃癌中免疫检查点抑制剂反应预测生物标志物的当前进展：如何最大化免疫治疗益处？
Cancers (Basel). 2023 Apr 13;15(8):2273. doi: 10.3390/cancers15082273.
4
Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review.免疫疗法在食管胃结合部癌治疗中的应用：实用综述。
JCO Oncol Pract. 2023 Mar;19(3):107-115. doi: 10.1200/OP.22.00226. Epub 2022 Nov 21.
一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
4
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.PD-L1 在胃癌中的表达：22C3 和 28-8 pharmDx 检测试剂用于免疫治疗应答的可互换性。
Mod Pathol. 2021 Sep;34(9):1719-1727. doi: 10.1038/s41379-021-00823-9. Epub 2021 May 17.
5
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.胃癌患者原发灶和局部转移灶配对的空间分析揭示了肿瘤转移的原则。
Gut. 2021 Oct;70(10):1823-1832. doi: 10.1136/gutjnl-2020-320805. Epub 2020 Nov 23.
6
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
7
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究：Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
8
Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?胃食管癌症的基因组分析与精准肿瘤学：向前还是向后？
Cancer Discov. 2018 Jan;8(1):14-16. doi: 10.1158/2159-8290.CD-17-1295.